Etnaaf 90 mg (Tablet)

Unit Price: ৳ 12.00 (3 x 10: ৳ 360.00)

Strip Price: ৳ 120.00

Medicine Details

Symptomatic relief of Osteoarthritis (OA)
Symptomatic relief of Rheumatoid arthritis (RA)
Symptomatic relief of Ankylosing spondylitis
Symptomatic relief of pain and signs of inflammation associated with acute gouty arthritis
Short-term treatment of moderate pain associated with dental surgery

Potent, orally active cyclooxygenase-2 (COX-2) specific inhibitor
Inhibition of COX-2 decreases clinical signs and symptoms with decreased potential for gastrointestinal (GI) toxicity and effects on platelet aggregation
Selective inhibition of COX-2 decreases pain, inflammation, and fever
Dose-dependent inhibition of COX-2 without inhibition of COX-1

Recommended dose for Osteoarthritis: 30 mg once daily, can be increased to 60 mg once daily in some patients
Recommended dose for Rheumatoid arthritis: 90 mg once daily
Recommended dose for Ankylosing spondylitis: 90 mg once daily
Recommended dose for Acute gouty arthritis: 120 mg once daily, for 8 days in clinical trials

Increase in prothrombin time when used with oral anticoagulants
Potential reduction in the effect of diuretics and other antihypertensive drugs when used with NSAIDs
Can be used concomitantly with low-dose acetylsalicylic acid for cardiovascular prophylaxis

Hypersensitivity to the active substance or to any of the excipients
Active peptic ulceration or active gastrointestinal (GI) bleeding
History of allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 inhibitors
Pregnancy and lactation
Severe hepatic dysfunction
Estimated renal creatinine clearance <30 ml/min
Children and adolescents under 16 years of age
Inflammatory bowel disease
Congestive heart failure (NYHA ll-IV)
Uncontrolled hypertension
Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease

Caution with patients at risk of developing gastrointestinal complications with NSAIDs
Consideration for patients with significant risk factors for cardiovascular events
Monitoring of renal function in patients with reduced prostaglandin formation
Caution in patients with history of cardiac failure, left ventricular dysfunction, or hypertension
Monitoring of liver function and discontinuation if signs of hepatic insufficiency occur
Discontinuation at the first appearance of hypersensitivity signs
Caution when co-administering with warfarin or other oral anticoagulants

No significant toxicity observed with single doses up to 500 mg and multiple doses up to 150 mg/day for 21 days
Usual supportive measures recommended in case of overdose